<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811509</url>
  </required_header>
  <id_info>
    <org_study_id>4604010730</org_study_id>
    <nct_id>NCT03811509</nct_id>
  </id_info>
  <brief_title>Breast Cancer Women on Aromatase Inhibitors Treatment</brief_title>
  <acronym>B-ABLE</acronym>
  <official_title>Study for Improving Life Quality in Breast Cancer Women Treated With Aromatase Inhibitors: Cohort B-ABLE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parc de Salut Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Parc de Salut Mar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to improve the life quality of women treated with AI.
      Cohort B-ABLE is designed to evaluate musculoskeletal events derived of using AI in breast
      cancer women. The project objectives are the analysis of the AI deleterious effect on bone
      microarchitecture and early determination of the risk of fragility fracture with dual energy
      x-ray absorptiometry (DEXA), lumbar spine Rx, Trabecular Bone Score (TBS) and
      microindentation. Determination of physiological causes of the AI-related arthralgia by
      analyzing joint degradation markers, steroid hormone levels remaining in blood and functional
      magnetic resonance, before and after three months of AI treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmenopausal women with breast cancer treated with aromatase inhibitors (AI) have a higher
      incidence of osteoporosis, fractures and other musculoskeletal symptoms, particularly pain
      and stiffness. B-ABLE is a clinical, prospective cohort study carried out in both Breast
      Cancer and Bone Metabolism Units of the Hospital del Mar in Barcelona. Currently, 780
      postmenopausal Caucasian women with early breast cancer and candidates for adjuvant AI
      treatment were included and predicted to reach more than 1000 patients. The main objective of
      the study is to improve the life quality of women treated with AI. Cohort B-ABLE is designed
      to evaluate musculoskeletal events derived of using AI in breast cancer women. The project
      objectives are the analysis of the AI deleterious effect on bone microarchitecture and early
      determination of the risk of fragility fracture with DEXA, lumbar spine Rx, TBS and
      microindentation. Determination of physiological causes of the AI-related arthralgia by
      analyzing joint degradation markers, steroid hormone levels remaining in blood and functional
      magnetic resonance, before and after three months of AI treatment. The study results will
      help to decide the most appropriate treatment for each patient in order to minimize
      AI-related side effects and hence avoid discontinuation of adjuvant therapy treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patents receive aromatase inhibitors Patients without osteoporosis receive only calcium and vitamin D Patients with osteoporosis receive antiresorptive treatment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone mass measured by dual energy x-ray absorptiometry (DEXA) densitometry</measure>
    <time_frame>change from baseline, 12 months, 24 months, 36 months, 48 months 60 months and 1 year after completion of aromatase treatment</time_frame>
    <description>bone mas normal, osteopenia or osteoporosis related with WHO definition of osteoporosis and Trabecular Bone Score: normal, mild degratation and high degradation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fragility fractures assessed by xRay</measure>
    <time_frame>incidence of new fractures at 12 months, 24 months, 36 months, 48 months 60 months of aromatase treatment</time_frame>
    <description>vertebral and non vertebral fractures, hip fractures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Strength (BMSi)</measure>
    <time_frame>change from baseline, 12 months, and 60 months of aromatase treatment</time_frame>
    <description>bone microindentation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arthralgia</measure>
    <time_frame>change from baseline, 12 months, 24 months, 36 months, 48 months 60 months and 1 year after completion of aromatase treatment</time_frame>
    <description>joint pain measured by analogic visual scale range 0= no pain 10= worse pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone turnover markers</measure>
    <time_frame>change from baseline, 12 months, 24 months, 36 months, 48 months 60 months and 1 year after completion of aromatase treatment</time_frame>
    <description>C-telopeptide (Ctx), Procollagen type 1 amino-terminal propeptide (P1NP) Bone Alkaline Phosphatase (AP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cartilage degradation markers</measure>
    <time_frame>change from baseline and 12 months of aromatase treatment</time_frame>
    <description>C-telopeptide II, Procollagen type 2 amino-terminal propeptide (P2NP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteoporosis Fracture</condition>
  <condition>Arthralgia Generalized</condition>
  <arm_group>
    <arm_group_label>AI with osteoporosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with osteoporosis receive intervention with antiresorptive treatment, bisphosphonates or denosumab . All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AI without osteoporosis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients receive calcium and Vit D supplements All patients receive by protocol aromatase inhibitors for breast cancer treatment, letrozole, exemestane for 5 o 10 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bisphosphonate</intervention_name>
    <description>antiresorptives</description>
    <arm_group_label>AI with osteoporosis</arm_group_label>
    <other_name>denosumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women with early breast cancer estrogen receptor with aromatase
             inhibitors treatment

        Exclusion Criteria:

          -  Previous treatment with antiresorptive treatment for osteoporosis secondary
             osteoporosis, as corticosteroids, Hyperparathyroidism, Kidney Chronic disease,
             previous treatment with aromatase inhibitors Diabetes mellitus type 1 Fibromyalgia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xavier Nogues, MD</last_name>
    <phone>34932483246</phone>
    <email>xnogues@parcdesalutmar.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Garcia-Giralt, PhD</last_name>
    <phone>34933160445</phone>
    <email>ngarcia@imim.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xavier Nogues</name>
      <address>
        <city>Barcelona</city>
        <zip>08015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Nogues, MD</last_name>
      <phone>932483246</phone>
      <email>xnogues@parcdesalutmar.cat</email>
    </contact>
    <contact_backup>
      <last_name>Natalia Garcia-Giralt, Phd</last_name>
      <phone>34933160445</phone>
    </contact_backup>
    <investigator>
      <last_name>Sonia Servitja, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignasi Tusquets, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Pineda, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Aymar</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaime Rodriguez-Morera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adolfo Díez-Pérez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Martinez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamara Martos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Servitja S, Nogués X, Prieto-Alhambra D, Martínez-García M, Garrigós L, Peña MJ, de Ramon M, Díez-Pérez A, Albanell J, Tusquets I. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast. 2012 Feb;21(1):95-101. doi: 10.1016/j.breast.2011.09.001. Epub 2011 Sep 15.</citation>
    <PMID>21924904</PMID>
  </reference>
  <reference>
    <citation>Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer. Maturitas. 2010 Jul;66(3):291-7. doi: 10.1016/j.maturitas.2010.03.012. Epub 2010 Apr 15.</citation>
    <PMID>20399042</PMID>
  </reference>
  <results_reference>
    <citation>Servitja S, Martos T, Rodriguez Sanz M, Garcia-Giralt N, Prieto-Alhambra D, Garrigos L, Nogues X, Tusquets I. Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance. Ther Adv Med Oncol. 2015 Sep;7(5):291-6. doi: 10.1177/1758834015598536. Review.</citation>
    <PMID>26327926</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>breast cancer</keyword>
  <keyword>microindentation</keyword>
  <keyword>arthralgia</keyword>
  <keyword>musculoskeletal pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Osteoporotic Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication in Oncology , Endocrinology and bone metabolism journals</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available in the next year and every time we have outcomes available</ipd_time_frame>
    <ipd_access_criteria>By asking CEIC Parc de Salut Mar</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

